Targeted protein degradation by hijacking endogenous pathways with chimeric molecules is currently revolutionizing the drug oncology field. Very recently, the innovative LYTAC concept showed for the first time the ability to induce degradation of therapeutically relevant proteins located on the surface of cancer cells. The initially reported LYTAC design is a rather ill-defined large hybrid protein-synthetic polymer construct and does not allow for tumor-selective protein degradation. In our project we will research an alternative strategy that allows for a more tumor-targeted activity.